Suggestions
Gregory Stock
CEO, Socratic Sciences; Founding Co-Director, Precision Wellness Center, Mt. Sinai Medical School; Founding CEO Signum Biosciences; Best-Selling Author; Public Speaker
Gregory Stock is a prominent figure in the fields of biophysics, biotechnology, and entrepreneurship. He currently serves as the Chief Executive Officer at Fathm.234 Here's a comprehensive overview of his background and accomplishments:
Education and Academic Background
Gregory Stock holds impressive academic credentials:
- PhD in Biophysics from Johns Hopkins University
- MBA from Harvard Business School, where he was a Baker Scholar and won the Freund-Porter Entrepreneurship award
- BS and MS degrees from Johns Hopkins University12
Professional Experience
Throughout his career, Stock has held various notable positions:
- CEO of Fathm, his current role234
- Former CEO of Signum Biosciences, a biotechnology company focused on developing small-molecule therapeutics1
- Former director of the Program on Medicine, Technology and Society at UCLA's School of Medicine1
- Adjunct Professor in the Department of Genetics2
Entrepreneurial Ventures
Stock has been involved in several entrepreneurial endeavors:
- Co-founder of Signum Biosciences in 20031
- Founding Co-Director of Precision Wellness Center at Mt. Sinai Medical Center5
Research and Expertise
His areas of interest and expertise include:
- Implications of the human genome project
- Molecular genetics and bioinformatics
- Ethical, social, and political implications of life sciences and information technology1
Publications and Public Engagement
Stock is a best-selling author and has been actively involved in public discussions:
- Written extensively on biotechnology's impact on society, medicine, and business
- Organized symposiums and debates on topics such as genome access and embryo genetic manipulation
- Regular speaker at academic, government, and business conferences
- Frequent appearances on media outlets like CNN, PBS, NPR, and the BBC1
Professional Affiliations
He has been associated with various organizations:
- Editorial board member of the American Journal of Bioethics
- Member of the California Advisory Committee on Stem Cells and Reproductive Cloning
- Associate director for the Bioagenda Institute and the Center for Life Science Studies at UC Berkeley1
Gregory Stock's diverse background in biophysics, business, and biotechnology has positioned him as a leading voice in discussions about the future of human genetics and biotechnology's role in society.
Highlights
The pace of today’s embrace of LLMs (Large Language Models) like Chat GPT, Claude, Bard, and such has been unprecedented.
The implications of this are profound as I recently discussed in my plenary talk at the N2 conference on the Noosphere (global mind) at UC Berkeley, marking the centenary of the first mention of “noosphere” — (Theillard de Chardin, 1923) - https://lnkd.in/gcfsXg2c
To spur thought about the coming fallout from this sudden AI evocation of human-like voice and content everywhere at scale, here’s a variant of a question that we at Socratic Sciences have posed elsewhere with surprising results.
(And please share your thinking, and the long-term consequences you hope for (or fear) from the explosion of LLM-shaped interaction.)
Next week, I’ll show the results here compared to similar surveys in academic and other environments.
This is the first in a weekly series here of challenging questions about the implications of emerging technology on business and society drawn from the embodiment of my Book of Questions series in Fathm (https://www.comefathm.com) by Socratic Sciences.
